AIM-listed Avacta Group provide an update to the market today on the MHRA status of SARS-CoV-2 Antigen Lateral Flow Test by its partner Mologic Limited.
The response from Avacta titled ‘response to speculation’ appeared to be provided due to a fake email that was fabricated by a private investor under the guise of the MHRA and doing the rounds across share chatter yesterday.
In the statement, Avacta reaffirmed that neither Avacta nor Mologic have had any update so far and as usual will confirm to the market when it has something to officially say on the matter:
To date, neither Avacta nor Mologic have received any update from the MHRA. Avacta will update the market when it is in a position to do so.Avacta – Response to speculation
The share price of Avacta tumbled slightly in the immediate aftermath of the announcement, but has since recovered to match yesterday’s closing price.